These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3586657)

  • 1. Triphenylethylene antiestrogen binding sites (TABS) specificity.
    Clark JH; Mitchell WC; Guthrie SC
    J Steroid Biochem; 1987 Apr; 26(4):433-7. PubMed ID: 3586657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcellular localization of triphenylethylene antiestrogen binding sites (TABS) in rat liver.
    Clark JH; Guthrie S
    J Steroid Biochem; 1986 Nov; 25(5A):635-9. PubMed ID: 2432354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a triphenylethylene-antiestrogen-binding site on rat serum low density lipoprotein.
    Winneker RC; Guthrie SC; Clark JH
    Endocrinology; 1983 May; 112(5):1823-7. PubMed ID: 6832070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triphenylethylene antiestrogen-binding sites in cockerel liver nuclei: evidence for an endogenous ligand.
    Murphy PR; Butts C; Lazier CB
    Endocrinology; 1984 Jul; 115(1):420-6. PubMed ID: 6734522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK; Sutherland RL
    Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiestrogen binding sites in rat liver nuclei.
    Kon OL
    Biochim Biophys Acta; 1985 Dec; 843(3):245-53. PubMed ID: 4063396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An endogenous ligand for the triphenylethylene antiestrogen binding site.
    Clark JH; Winneker RC; Guthrie SC; Markaverich BM
    Endocrinology; 1983 Sep; 113(3):1167-9. PubMed ID: 6872955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical and genetic evidence for specific antiestrogen binding sites.
    Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of oxygenated cholesterol metabolites to antiestrogen binding sites from chicken liver.
    Murphy PR; Breckenridge WC; Lazier CB
    Biochem Biophys Res Commun; 1985 Mar; 127(3):786-92. PubMed ID: 3985957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells.
    Gulino A; Barrera G; Vacca A; Farina A; Ferretti C; Screpanti I; Dianzani MU; Frati L
    Cancer Res; 1986 Dec; 46(12 Pt 1):6274-8. PubMed ID: 3022916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.
    Lyman SD; Jordan VC
    Biochem Pharmacol; 1985 Aug; 34(15):2795-806. PubMed ID: 4015716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of estrogen and antiestrogen binding to the estrogen receptor by diethylpyrocarbonate.
    Borgna JL; Scali J
    J Steroid Biochem; 1988 Oct; 31(4A):427-36. PubMed ID: 3050278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-affinity binding sites for oxygenated sterols in rat liver microsomes: possible identity with antiestrogen binding sites.
    Hwang PL
    Biochim Biophys Acta; 1990 Feb; 1033(2):154-61. PubMed ID: 2306459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of binding sites for tamoxifen and tamoxifen derivatives in estrogen target and nontarget fetal organs of guinea pig.
    Gulino A; Pasqualini JR
    Cancer Res; 1982 May; 42(5):1913-21. PubMed ID: 7066903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site.
    Murphy LC; Sutherland RL
    J Clin Endocrinol Metab; 1983 Aug; 57(2):373-9. PubMed ID: 6408114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative affinity of steroidal and non-steroidal antioestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antioestrogen binding site.
    van den Koedijk CD; Vis van Heemst C; Elsendoorn GM; Thijssen JH; Blankenstein MA
    Biochem Pharmacol; 1992 Jun; 43(12):2511-8. PubMed ID: 1632810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of action of LN 1643 (a triphenylbromoethylene antiestrogen): probable mediation by the estrogen receptor and high affinity metabolite.
    Borgna JL; Coezy E; Rochefort H
    Biochem Pharmacol; 1982 Oct; 31(20):3187-91. PubMed ID: 7150347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.